Finasteride, a well-known 5α-reductase inhibitor, also effectively decreased the expression of Srd5a2. These results indicate that one of the modes of action by which PCE reduces BPH symptoms is similar to that of finasteride. The gene discussed is SRD5A2; the disease is benign prostatic hyperplasia.